Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

1.550 UNCHANGED
Streaming Delayed Price Updated: 10:35 AM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Director
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chairman
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chairman
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Successful Type C Meeting with the FDA
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach 
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Ring the Opening Bell at Nasdaq
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS